INTERSTITIAL LUNG DISEASE AND DIFFUSE ALVEOLAR HEMORRHAGE IN THE PRESENCE OF FAM-TRASTUZUMAB DERUXTECAN-NXKI (ENHERTU) FOR STAGE IV BREAST CANCER

被引：0
|
作者：
Perez, Hector I. Roman
Sesemann, Lauren
Zero, Natalia
Kregor, Alexandria Clarke
Park, Yoonho
Coughlin, Colin
机构：
来源：
CHEST | 2023年 / 164卷 / 04期
关键词：
D O I：
10.1016/j.chest.2023.07.2220
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：3416A / 3417A
页数：2
相关论文
共 25 条
  • [1] Desensitization Protocol to Fam-trastuzumab Deruxtecan-nxki (Enhertu)
    Budhan, S.
    Szema, A. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [2] Fam-Trastuzumab Deruxtecan-nxki in metastatic HER2-low breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (07) : 779 - 779
  • [3] A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer
    Nguyen, Xoan
    Hooper, Morgan
    Borlagdan, Jared Paul
    Palumbo, Alison
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (11) : 1410 - 1418
  • [4] FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer
    Narayan, Preeti
    Osgood, Christy L.
    Singh, Harpreet
    Chiu, Haw-Jyh
    Ricks, Tiffany K.
    Chow, Edwin Chiu Yuen
    Qiu, Junshan
    Song, Pengfei
    Yu, Jingyu
    Namuswe, Frances
    Guiterrez-Lugo, Maria
    Hou, Sherry
    Pierce, William F.
    Goldberg, Kirsten B.
    Tang, Shenghui
    Amiri-Kordestani, Laleh
    Theoret, Marc R.
    Pazdur, Richard
    Beaver, Julia A.
    CLINICAL CANCER RESEARCH, 2021, 27 (16) : 4478 - 4485
  • [5] DRAMATIC RESPONSE OF ERBB2 POSITIVE BRAIN METASTASES FROM LUNG ADENOCARCINOMA TO FAM-TRASTUZUMAB DERUXTECAN-NXKI
    Thompson, Tracy
    Luster, Sara
    Savvides, Panayiotis
    Sio, Terence
    Westerlund, Lynsey
    Fortin-Ensign, Shannon
    Mrugala, Maciej
    NEURO-ONCOLOGY, 2022, 24 : 141 - 141
  • [6] Enhertu (Fam-trastuzumab-deruxtecan-nxki) - Revolutionizing treatment paradigm for HER2-Low breast cancer
    Siddiqui, Tasmiyah
    Rani, Payal
    Ashraf, Tayyaba
    Ellahi, Aayat
    ANNALS OF MEDICINE AND SURGERY, 2022, 82
  • [7] FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations
    Mehta, Gautam U.
    Vellanki, Paz J.
    Ren, Yi
    Amatya, Anup K.
    Mishra-Kalyani, Pallavi S.
    Pan, Lili
    Zirkelbach, Jeanne F.
    Pan, Yuzhuo
    Liu, Jiang
    Aungst, Stephanie L.
    Miller, Claudia P.
    Shah, Mirat
    Rahman, Nam Atiqur
    Theoret, Marc
    Kluetz, Paul
    Pazdur, Richard
    Beaver, Julia A.
    Singh, Harpreet
    ONCOLOGIST, 2024, 29 (08): : 667 - 671
  • [8] US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer
    Narayan, Preeti
    Dilawari, Asma
    Osgood, Christy
    Feng, Zhou
    Bloomquist, Erik
    Pierce, William F.
    Jafri, Samina
    Kalavar, Shyam
    Kondratovich, Marina
    Jha, Prakash
    Ghosh, Soma
    Tang, Shenghui
    Pazdur, Richard
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (11) : 2108 - +
  • [9] CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With Fam-Trastuzumab Deruxtecan: A Single Institutional Experience
    Jang, Yoon Jung
    Jeong, Jae Ho
    Kim, Jeong Eun
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Kim, Sung-Bae
    JOURNAL OF BREAST CANCER, 2022, 25 (01) : 49 - 56
  • [10] Feasibility of a comprehensive monitoring protocol for the prevention and treatment of interstitial lung disease in patients undergoing treatment with fam-trastuzumab deruxtecan
    Moore, Heather
    Shofer, Scott
    Guisinger, Amy
    Broadwater, Gloria
    Force, Jeremy
    Sammons, Sarah
    Anders, Carey
    Westbrook, Kelly
    CANCER RESEARCH, 2021, 81 (04)
123